Hungary: These 5 Drugs Face Patent Expirations and Generic Entry in 2025 - 2026
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Hungary
Generic Entry Dates in Other Countries
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
Summary: Hungary: These 5 Drugs Face Patent Expirations and Generic Entry in 2025 - 2026
| Tradename | Ingredient | Estimated Entry Opportunity Date |
|---|---|---|
| EMBEDA | morphine sulfate; naltrexone hydrochloride | 2026-06-19 |
| OLYSIO | simeprevir sodium | 2026-07-28 |
| PICATO | ingenol mebutate | 2026-12-18 |
| TRADJENTA | linagliptin | 2026-05-04 |
| VAFSEO | vadadustat | 2026-06-26 |
| >Tradename | >Ingredient | >Estimated Entry Opportunity Date |
Details: Hungary: These 5 Drugs Face Patent Expirations and Generic Entry in 2025 - 2026
When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch?
Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2026
Generic Entry Controlled by: Hungary Patent E032156
EMBEDA is a drug marketed by Alpharma Pharms. There are nine patents protecting this drug and four Paragraph IV challenges.
This drug has seventy-four patent family members in twenty-three countries.
See drug price trends for EMBEDA.
The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this API. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 28, 2026
Generic Entry Controlled by: Hungary Patent E027156
OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.
This drug has one hundred and forty patent family members in forty-three countries.
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can PICATO (ingenol mebutate) generic drug versions launch?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 18, 2026
Generic Entry Controlled by: Hungary Patent E020998
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can TRADJENTA (linagliptin) generic drug versions launch?
Generic name: linagliptin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 04, 2026
Generic Entry Controlled by: Hungary Patent E025210
This drug has four hundred and eighty-six patent family members in forty-five countries. There has been litigation on patents covering TRADJENTA
See drug price trends for TRADJENTA.
The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.
When can VAFSEO (vadadustat) generic drug versions launch?
Generic name: vadadustat
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 26, 2026
Generic Entry Controlled by: Hungary Patent E059557
VAFSEO is a drug marketed by Akebia. There are thirteen patents protecting this drug.
This drug has two hundred and fifty-eight patent family members in forty-eight countries. There has been litigation on patents covering VAFSEO
The generic ingredient in VAFSEO is vadadustat. One supplier is listed for this generic product. Additional details are available on the vadadustat profile page.
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch